Impairment of functional integrity of the vasculature is not changed in patients starting abacavir
© Zona et al; licensee BioMed Central Ltd. 2008
Published: 10 November 2008
Purpose of the study
In order to explore a possible pathogenetic mechanism of abacavir (ABC) cardiovascular toxicity, we assess the impact of beginning the drug on endothelial function via assessment of brachial artery diameter (BAD) and flow-mediated dilation (FMD).
Cross-sectional observational study that included all consecutive HIV-infected patients seen at a metabolic clinic who had BAD and FMD evaluation before and 9 months after beginning ABC as a component of a new drug regimen.
Summary of results
Change in impairment of functional integrity of the vasculature is not an associated factor related with ABC use. Cardiovascular disease risk among HIV-infected HAART-experienced persons is likely governed by complex pathophysiologic and treatment factors.
This article is published under license to BioMed Central Ltd.